Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors - PubMed (original) (raw)
Comparative Study
. 2003 Feb;162(2):469-77.
doi: 10.1016/S0002-9440(10)63841-2.
Patrick Franken, Jan Willem Dierssen, Wiljo De Leeuw, Juul Wijnen, Enno Dreef, Carli Tops, Martijn Breuning, Annette Bröcker-Vriends, Hans Vasen, Riccardo Fodde, Hans Morreau
Affiliations
- PMID: 12547705
- PMCID: PMC1851154
- DOI: 10.1016/S0002-9440(10)63841-2
Comparative Study
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors
Yvonne Hendriks et al. Am J Pathol. 2003 Feb.
Abstract
Immunohistochemistry (IHC) of mismatch repair (MMR) proteins in colorectal tumors together with microsatellite analysis (MSI) can be helpful in identifying families eligible for mutation analysis. The aims were to determine sensitivity of IHC for MLH1, MSH2, and MSH6 and MSI analysis in tumors from known MMR gene mutation carriers; and to evaluate the use of tissue microarrays for IHC (IHC-TMA) of colon tumors in its ability to identify potential carriers of MMR gene mutations, and compare it with IHC on whole slides. IHC on whole slides was performed in colorectal tumors from 45 carriers of a germline mutation in one of the MMR genes. The TMA cohort consisted of 129 colon tumors from (suspected) hereditary nonpolyposis colorectal cancer (HNPCC) patients. Whole slide IHC analysis had a sensitivity of 89% in detecting MMR deficiency in carriers of a pathogenic MMR mutation. Sensitivity by MSI analysis was 93%. IHC can also be used to predict which gene is expected to harbor the mutation: for MLH1, MSH2, and MSH6, IHC on whole slides would have correctly predicted the mutation in 48%, 92%, and 75% of the cases, respectively. We propose a scheme for the diagnostic approach of families with (suspected) HNPCC. Comparison of the IHC results based on whole slides versus TMA, showed a concordance of 85%, 95%, and 75% for MLH, MSH2, and MSH6, respectively. This study therefore shows that IHC-TMA can be reliably used to simultaneously screen a large number of tumors from (suspected) HNPCC patients, at first in a research setting.
Figures
Figure 1.
Immunoreactivity in a TMA of mainly (suspected) HNPCC patients. A tissue core with a colon carcinoma from a patient with a germline hMLH1 missense mutation (1744C>T, L582F) is shown, stained for MLH1 (A), MSH2 (B), and MSH6 (C). MLH1 is abrogated, whereas MSH2 and MSH6 are present in the nuclei of the tumor cells. Slides were stained with antibodies against MLH1 (clone 14, Calbiochem, Cambridge, MA), MSH2 (clone GB12, Calbiochem), and MSH6 (clone 44, Transduction Laboratories/Becton Dickinson, Lexington, KY). Original magnifications, ×100.
Figure 2.
Approach of patients with familial clustering of CRC. 1: IHC for MLH1, MSH2, MSH6, PMS2. 2: If the tumor is MSI-H, mutation analysis is the next step. 3: If the tumor is MSI-H and mutation has already been performed, research is the next step.
Similar articles
- Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T, Godino J, Sanchez A, Corbacho C, De la Hoya M, Lopez Asenjo J, Saez C, Sanz J, Benito M, Ramon Y Cajal S, Diaz-Rubio E. Caldés T, et al. Oncol Rep. 2004 Sep;12(3):621-9. Oncol Rep. 2004. PMID: 15289847 - Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.
Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, Gerald WL, Ellis NA. Shia J, et al. Am J Surg Pathol. 2005 Jan;29(1):96-104. doi: 10.1097/01.pas.0000146009.85309.3b. Am J Surg Pathol. 2005. PMID: 15613860 - Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U, Müller-Koch Y, Gross M, Daum J, Lohse P, Baretton G, Muders M, Mussack T, Kopp R, Holinski-Feder E. Schiemann U, et al. Digestion. 2004;69(3):166-76. doi: 10.1159/000078223. Epub 2004 Apr 28. Digestion. 2004. PMID: 15118395 - A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome.
Barrow E, Evans DG, McMahon R, Hill J, Byers R. Barrow E, et al. J Clin Pathol. 2011 Mar;64(3):208-14. doi: 10.1136/jcp.2010.084418. Epub 2010 Dec 22. J Clin Pathol. 2011. PMID: 21177748 Review. - Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
Vasen HF, Hendriks Y, de Jong AE, van Puijenbroek M, Tops C, Bröcker-Vriends AH, Wijnen JT, Morreau H. Vasen HF, et al. Dis Markers. 2004;20(4-5):207-13. doi: 10.1155/2004/391039. Dis Markers. 2004. PMID: 15528786 Free PMC article. Review.
Cited by
- Comparison of Microsatellite Instability With Clinicopathologic Data in Patients With Colon Adenocarcinoma.
Cesmecioglu Karavin E, Sağnak Yılmaz Z, Yazici H, Ersoz S, Mungan S. Cesmecioglu Karavin E, et al. Cureus. 2024 Apr 8;16(4):e57814. doi: 10.7759/cureus.57814. eCollection 2024 Apr. Cureus. 2024. PMID: 38590982 Free PMC article. - Tissue microarrey: a potential cost-effective approach for mismatch repair testing in colorectal cancer.
Farkash S, Schwartz N, Edison N, Greenberg S, Peled HB, Sindiany W, Krausz J. Farkash S, et al. BMC Gastroenterol. 2022 Dec 8;22(1):504. doi: 10.1186/s12876-022-02573-7. BMC Gastroenterol. 2022. PMID: 36482310 Free PMC article. - Prevalence and Genotype-Phenotype Correlation of Lynch Syndrome in a Selected High-Risk Cohort from Qatar's Population.
Sidenna M, Khodjet-El-Khil H, Al Mulla H, Al-Shafai M, Habish HH, Al-Sulaiman R, Al-Bader SB. Sidenna M, et al. Genes (Basel). 2022 Nov 21;13(11):2176. doi: 10.3390/genes13112176. Genes (Basel). 2022. PMID: 36421850 Free PMC article. - Reg4 and its downstream transcriptional activator CD44ICD in stage II and III colorectal cancer.
Sninsky JA, Bishnupuri KS, González I, Trikalinos NA, Chen L, Dieckgraefe BK. Sninsky JA, et al. Oncotarget. 2021 Feb 16;12(4):278-291. doi: 10.18632/oncotarget.27896. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659040 Free PMC article. - Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer.
Wang SM, Jiang B, Deng Y, Huang SL, Fang MZ, Wang Y. Wang SM, et al. World J Gastrointest Oncol. 2019 Nov 15;11(11):1065-1080. doi: 10.4251/wjgo.v11.i11.1065. World J Gastrointest Oncol. 2019. PMID: 31798786 Free PMC article.
References
- Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170 - PubMed
- Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993, 104:1535-1549 - PubMed
- Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998, 338:1481-1487 - PubMed
- Vasen HF, Mecklin JP, Khan PM, Lynch HT: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425 - PubMed
- Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116:1453-1456 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous